Welcome to the era of mindful medicine.

Psilera is developing next-generation neuroplastogens for neurological disorders.

The Latest From The Lab:

Psilera Collaborates with Drug Development Leader Hesperos to Advance Preclinical Modeling of PSIL-006.

Read the full press release here!

Psilera

At A

Glance

  • We have created and developed six separate serotonergic compound families.

  • Two patents have been issued from the USPTO covering over 1 million novel compounds. Several more patents expected by 1H 2024.

  • The Psilera leadership team has over 100 years of combined experience in the biotech and pharmaceutical industries.

  • Our best-in-class proprietary compound library has coverage for over 1 million novel compounds.

  • Psilera’s co-founders bring over $1.5B in cumulative value created from prior start-ups.

Psilera is revolutionizing how small molecule drug discovery is done, giving rise to more patient-centric therapy options for those suffering from neurological conditions.

Based on the current pipeline, our focus is on hard-to-treat disorders, many of which have no currently available treatments, such as Frontotemporal Dementia (FTD).

UPCOMING EVENTS

UPCOMING EVENTS

September 9 - 11


Boston, MA

November 13 - 14


Madison, WI

Neuropsychiatric Drug Development Summit

Jackie von Salm, PhD will be in Boston for the 8th Annual Neuropsychiatric Drug Development Summit. Dr. von Salm will be hosting a workshop highlight the exciting discoveries being made in neuroplastogenic research. If you would like to connect with her while she is in Boston, please contact info@psilera.com to arrange a time.

Psychedelic Symposium

Jackie von Salm, PhD will be in Boston for the UW Madison Psychedelic Symposium. The event is aimed at expanding awareness, fostering knowledge exchange, and bridging gaps in psychedelic research, education, and policy. If you would like to connect with her while she is at the Symposium, please contact info@psilera.com to arrange a time.